{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:31:49Z","timestamp":1792067509643,"version":"4.4.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-023-10370-x","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T09:01:34Z","timestamp":1700902894000},"page":"431-444","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Clinical staging of Anderson-Fabry cardiomyopathy: An operative proposal"],"prefix":"10.1007","volume":"29","author":[{"given":"Annamaria","family":"Del Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Iannaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Meucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Lillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pieroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Graziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,25]]},"reference":[{"key":"10370_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","volume":"26","author":"F Weidemann","year":"2005","unstructured":"Weidemann F, Breunig F, Beer M, Sandstede J, St\u00f6rk S, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM (2005) The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26:1221\u20131227. https:\/\/doi.org\/10.1093\/eurheartj\/ehi143","journal-title":"Eur Heart J"},{"key":"10370_CR2","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","volume":"77","author":"M Pieroni","year":"2021","unstructured":"Pieroni M, Moon JC, Arbustini E, Barriales-Villa R, Camporeale A, Vujkovac AC, Elliott PM, Hagege A, Kuusisto J, Linhart A, Nordbeck P, Olivotto I, Pietil\u00e4-Effati P, Namdar M (2021) Cardiac involvement in Fabry disease: JACC review topic of the week. J Am Coll Cardiol 77:922\u2013936. https:\/\/doi.org\/10.1016\/j.jacc.2020.12.024","journal-title":"J Am Coll Cardiol"},{"key":"10370_CR3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jmg.2008.065904","volume":"46","author":"A Mehta","year":"2009","unstructured":"Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G, Investigators FOS (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry outcome survey. J Med Genet 46:548\u2013552. https:\/\/doi.org\/10.1136\/jmg.2008.065904","journal-title":"J Med Genet"},{"key":"10370_CR4","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jacc.2022.06.022","volume":"80","author":"C Orsborne","year":"2022","unstructured":"Orsborne C, Bradley J, Bonnett LJ, Pleva LA, Naish JH, Clark DG, Abidin N, Woolfson P, Nucifora G, Schmitt M, Jovanovic A, Miller CA, Reid AB (2022) Validated model for prediction of adverse cardiac outcome in patients with Fabry disease. J Am Coll Cardiol 80:982\u2013994. https:\/\/doi.org\/10.1016\/j.jacc.2022.06.022","journal-title":"J Am Coll Cardiol"},{"key":"10370_CR5","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.jcmg.2018.03.020","volume":"12","author":"S Nordin","year":"2019","unstructured":"Nordin S, Kozor R, Medina-Menacho K, Abdel-Gadir A, Baig S, Sado DM, Lobascio I, Murphy E, Lachmann RH, Mehta A, Edwards NC, Ramaswami U, Steeds RP, Hughes D, Moon JC (2019) Proposed stages of myocardial phenotype development in Fabry disease. JACC Cardiovasc Imaging 12:1673\u20131683. https:\/\/doi.org\/10.1016\/j.jcmg.2018.03.020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10370_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, Jabbour F, Beldjord C, De Mazancourt P, Germain DP (2016) X-chromosome inactivation in female patients with Fabry disease. Clin Genet 89:44\u201354. https:\/\/doi.org\/10.1111\/cge.12613","journal-title":"Clin Genet"},{"key":"10370_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2019.100454","volume":"19","author":"DP Germain","year":"2019","unstructured":"Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, Kantola I, Linhart A, Mignani R, Namdar M, Nowak A, Oliveira JP, Pieroni M, Viana-Baptista M, Wanner C, Spada M (2019) The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts. Mol Genet Metab Rep 19:100454. https:\/\/doi.org\/10.1016\/j.ymgmr.2019.100454","journal-title":"Mol Genet Metab Rep"},{"key":"10370_CR8","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.jacc.2023.07.02","volume":"82","author":"MC Meucci","year":"2023","unstructured":"Meucci MC, Lillo R, Del Franco A, Monda E, Iannaccone G, Baldassarre R, Di Nicola F, Parisi V, Lombardo A, Spinelli L, Biagini E, Pieroni M, Pisani A, Crea F, Iaccarino G, Limongelli G, Olivotto I, Graziani F (2023) Prognostic implications of the extent of cardiac damage in patients with Fabry disease. J Am Coll Cardiol 82:1524\u20131534. https:\/\/doi.org\/10.1016\/j.jacc.2023.07.02","journal-title":"J Am Coll Cardiol"},{"key":"10370_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1161\/CIRCHEARTFAILURE.112.967026","volume":"5","author":"I Olivotto","year":"2012","unstructured":"Olivotto I, Cecchi F, Poggesi C, Yacoub MH (2012) Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail 5:535\u2013546. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.112.967026","journal-title":"Circ Heart Fail"},{"key":"10370_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.amjcard.2017.04.016","volume":"120","author":"HC Wilson","year":"2017","unstructured":"Wilson HC, Hopkin RJ, Madueme PC, Czosek RJ, Bailey LA, Taylor MD, Jefferies JL (2017) Arrhythmia and clinical cardiac findings in children with Anderson-Fabry disease. Am J Cardiol 120:251\u2013255. https:\/\/doi.org\/10.1016\/j.amjcard.2017.04.016","journal-title":"Am J Cardiol"},{"key":"10370_CR11","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1007\/s12265-020-10097-2","volume":"14","author":"A Hern\u00e1ndez-Hern\u00e1ndez","year":"2021","unstructured":"Hern\u00e1ndez-Hern\u00e1ndez A, Diez-L\u00f3pez C, Azevedo O, Palomino-Doza J, Alfonso F, Fuentes-Ca\u00f1amero ME, Mogoll\u00f3n Jim\u00e9nez MV, Casanova Rodr\u00edguez C, Ruz A, Tir\u00f3n C, Climent V, Garcia-Pavia P (2021) Screening of Fabry disease in patients with chest pain without obstructive coronary artery disease. J Cardiovasc Transl Res 14:948\u2013950. https:\/\/doi.org\/10.1007\/s12265-020-10097-2","journal-title":"J Cardiovasc Transl Res"},{"key":"10370_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1253\/circj.CJ-18-0734","volume":"83","author":"Y Kitani","year":"2019","unstructured":"Kitani Y, Nakagawa N, Sakamoto N, Takeuchi T, Takahashi F, Momosaki K, Nakamura K, Endo F, Maruyama H, Hasebe N (2019) Unexpectedly high prevalence of coronary spastic angina in patients with Anderson-Fabry disease. Circ J 83:481\u2013484. https:\/\/doi.org\/10.1253\/circj.CJ-18-0734","journal-title":"Circ J"},{"key":"10370_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1161\/CIRCHEARTFAILURE.108.769729","volume":"1","author":"C Chimenti","year":"2008","unstructured":"Chimenti C, Morgante E, Tanzilli G, Mangieri E, Critelli G, Gaudio C, Russo MA, Frustaci A (2008) Angina in Fabry disease reflects coronary small vessel disease. Circ Heart Fail 1:161\u2013169. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.108.769729","journal-title":"Circ Heart Fail"},{"key":"10370_CR14","doi-asserted-by":"publisher","unstructured":"Coughlan JJ, Elkholy K, O'Brien J, Kiernan T (2016) Atypical patterns of cardiac involvement in Fabry disease. BMJ Case Rep 2016:bcr2015213819.\u00a0https:\/\/doi.org\/10.1136\/bcr-2015-213819","DOI":"10.1136\/bcr-2015-213819"},{"key":"10370_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.119.009104","volume":"12","author":"F Graziani","year":"2019","unstructured":"Graziani F, Lillo R, Panaioli E, Spagnoletti G, Bruno I, Leccisotti L, Marano R, Manna R, Crea F (2019) Massive coronary microvascular dysfunction in severe Anderson-Fabry disease cardiomyopathy. Circ Cardiovasc Imaging 12:e009104. https:\/\/doi.org\/10.1161\/CIRCIMAGING.119.009104","journal-title":"Circ Cardiovasc Imaging"},{"key":"10370_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1136\/hrt.2004.054015","volume":"92","author":"PM Elliott","year":"2006","unstructured":"Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, Thaman R, Tome MT, McKenna WJ, Lee P, Camici PG (2006) Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 92:357\u2013360. https:\/\/doi.org\/10.1136\/hrt.2004.054015","journal-title":"Heart"},{"key":"10370_CR17","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.3390\/jcm10194422","volume":"10","author":"A Roy","year":"2021","unstructured":"Roy A, Umar H, Ochoa-Ferraro A, Warfield A, Lewis N, Geberhiwot T, Steeds R (2021) Atherosclerosis in Fabry disease-a contemporary review. J Clin Med 10:4422. https:\/\/doi.org\/10.3390\/jcm10194422","journal-title":"J Clin Med"},{"key":"10370_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029427","volume":"101","author":"S Zhou","year":"2022","unstructured":"Zhou S, Wang X, Xu H, Li J, Zhang L, Li H (2022) Fabry disease with acute myocardial infarction, left ventricular thrombosis, and pericardial effusion: a case report. Medicine (Baltimore) 101:e29427. https:\/\/doi.org\/10.1097\/MD.0000000000029427","journal-title":"Medicine (Baltimore)"},{"key":"10370_CR19","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","volume":"28","author":"A Linhart","year":"2007","unstructured":"Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, Elliott PM, European FOS investigators (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28:1228\u20131235. https:\/\/doi.org\/10.1093\/eurheartj\/ehm153","journal-title":"Eur Heart J"},{"key":"10370_CR20","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/ehf2.13101","volume":"8","author":"F Graziani","year":"2021","unstructured":"Graziani F, Lillo R, Panaioli E, Spagnoletti G, Pieroni M, Ferrazzi P, Camporeale A, Verrecchia E, Sicignano LL, Manna R, Crea F (2021) Evidence of evolution towards left midventricular obstruction in severe Anderson-Fabry cardiomyopathy. ESC Heart Fail 8:725\u2013728. https:\/\/doi.org\/10.1002\/ehf2.13101","journal-title":"ESC Heart Fail"},{"key":"10370_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.amjcard.2021.03.042","volume":"150","author":"D Zem\u00e1nek","year":"2021","unstructured":"Zem\u00e1nek D, Marek J, Dost\u00e1lov\u00e1 G, Magage S, Roblov\u00e1 L, Kov\u00e1rn\u00edk T, Linhart A (2021) Usefulness of alcohol septal ablation in the left ventricular outflow tract obstruction in Fabry disease cardiomyopathy. Am J Cardiol 150:110\u2013113. https:\/\/doi.org\/10.1016\/j.amjcard.2021.03.042","journal-title":"Am J Cardiol"},{"key":"10370_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijcard.2019.06.042","volume":"292","author":"Z Meghji","year":"2019","unstructured":"Meghji Z, Nguyen A, Miranda WR, Geske JB, Schaff HV, Peck DS, Newman DB (2019) Surgical septal myectomy for relief of dynamic obstruction in Anderson-Fabry disease. Int J Cardiol 292:91\u201394. https:\/\/doi.org\/10.1016\/j.ijcard.2019.06.042","journal-title":"Int J Cardiol"},{"key":"10370_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/pgmj.62.726.285","volume":"62","author":"J Efthimiou","year":"1986","unstructured":"Efthimiou J, McLelland J, Betteridge DJ (1986) Short PR intervals and tachyarrhythmias in Fabry\u2019s disease. Postgrad Med J 62:285\u2013287. https:\/\/doi.org\/10.1136\/pgmj.62.726.285","journal-title":"Postgrad Med J"},{"key":"10370_CR24","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1136\/hrt.2010.196162","volume":"96","author":"C Chimenti","year":"2010","unstructured":"Chimenti C, Russo MA, Frustaci A (2010) Atrial biopsy evidence of Fabry disease causing lone atrial fibrillation. Heart 96:1782\u20131783. https:\/\/doi.org\/10.1136\/hrt.2010.196162","journal-title":"Heart"},{"key":"10370_CR25","doi-asserted-by":"publisher","unstructured":"Kim H, Kang MG, Park HW, Park JR, Hwang JY, Kim K (2021) Anderson-Fabry disease presenting with atrial fibrillation as earlier sign in a young patient: a case report. World J Clin Cases 9:4823\u20134828.\u00a0https:\/\/doi.org\/10.12998\/wjcc.v9.i18.4823","DOI":"10.12998\/wjcc.v9.i18.4823"},{"key":"10370_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ijcard.2015.01.001","volume":"182","author":"P Qian","year":"2015","unstructured":"Qian P, Ross D, Tchan M, Sadick N (2015) A patient with recurrent disabling atrial fibrillation and Fabry cardiomyopathy successfully treated with single ring pulmonary vein isolation. Int J Cardiol 182:375\u2013376. https:\/\/doi.org\/10.1016\/j.ijcard.2015.01.001","journal-title":"Int J Cardiol"},{"key":"10370_CR27","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.amjcard.2016.04.033","volume":"118","author":"F Weidemann","year":"2016","unstructured":"Weidemann F, Maier SK, St\u00f6rk S, Brunner T, Liu D, Hu K, Seydelmann N, Schneider A, Becher J, Canan-K\u00fchl S, Blaschke D, Bijnens B, Ertl G, Wanner C, Nordbeck P (2016) Usefulness of an implantable loop recorder to detect clinically relevant arrhythmias in patients with advanced Fabry cardiomyopathy. Am J Cardiol 118:264\u2013274. https:\/\/doi.org\/10.1016\/j.amjcard.2016.04.033","journal-title":"Am J Cardiol"},{"key":"10370_CR28","doi-asserted-by":"publisher","unstructured":"Pavlu L, Kocourkova L, Taborsky M, Petrkova J (2018) Ventricular tachycardia: a presentation of Fabry disease case report. Eur Heart J Case Rep 3:yty154.\u00a0https:\/\/doi.org\/10.1093\/ehjcr\/yty154","DOI":"10.1093\/ehjcr\/yty154"},{"key":"10370_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1148\/radiol.2019191385","volume":"294","author":"K Hanneman","year":"2020","unstructured":"Hanneman K, Karur GR, Wasim S, Wald RM, Iwanochko RM, Morel CF (2020) Left ventricular hypertrophy and late gadolinium enhancement at cardiac MRI are associated with adverse cardiac events in Fabry disease. Radiology 294:42\u201349. https:\/\/doi.org\/10.1148\/radiol.2019191385","journal-title":"Radiology"},{"key":"10370_CR30","doi-asserted-by":"publisher","unstructured":"Silva-Gburek J, Rochford L, Hopkin R, Jefferies JL (2016) Ventricular tachycardia in Fabry disease detected in a 50-year-old woman during 14-day continuous cardiac monitoring. Tex Heart Inst J 43:531\u2013533. https:\/\/doi.org\/10.14503\/THIJ-15-5572","DOI":"10.14503\/THIJ-15-5572"},{"key":"10370_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.hrcr.2021.11.025","volume":"8","author":"G Ditac","year":"2021","unstructured":"Ditac G, Gardey K, Jobb\u00e9-Duval A, Fouilhoux A, Millat G, Chevalier P (2021) Late-onset Fabry disease revealed by ventricular tachycardia: a case report. HeartRhythm Case Rep 8:79\u201383. https:\/\/doi.org\/10.1016\/j.hrcr.2021.11.025","journal-title":"HeartRhythm Case Rep"},{"key":"10370_CR32","doi-asserted-by":"publisher","unstructured":"Mills MT, Nelson TA, Kelland NF, Sahu J, Lee J, Lewis N, Hiwot T, Kyriacou AL (2021) Radiofrequency ablation of ventricular tachycardia in Anderson-Fabry disease: a case series. Eur Heart J Case Rep 5:ytaa529. https:\/\/doi.org\/10.1093\/ehjcr\/ytaa529","DOI":"10.1093\/ehjcr\/ytaa529"},{"key":"10370_CR33","doi-asserted-by":"publisher","first-page":"f153","DOI":"10.1093\/europace\/eux261","volume":"20","author":"S Baig","year":"2018","unstructured":"Baig S, Edward NC, Kotecha D, Liu B, Nordin S, Kozor R, Moon JC, Geberhiwot T, Steeds RP (2018) Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice. Europace 20:f153\u2013f161. https:\/\/doi.org\/10.1093\/europace\/eux261","journal-title":"Europace"},{"key":"10370_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004996","volume":"95","author":"T Sen\u00e9","year":"2016","unstructured":"Sen\u00e9 T, Lidove O, Sebbah J, Darondel JM, Picard H, Aaron L, Fain O, Zenone T, Joly D, Charron P, Ziza JM (2016) Cardiac device implantation in Fabry disease: a retrospective monocentric study. Medicine (Baltimore) 95:e4996. https:\/\/doi.org\/10.1097\/MD.0000000000004996","journal-title":"Medicine (Baltimore)"},{"key":"10370_CR35","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/0002-8703(90)90096-g","volume":"120","author":"M Suzuki","year":"1990","unstructured":"Suzuki M, Goto T, Kato R, Yamauchi K, Hayashi H (1990) Combined atrioventricular block and sinus node dysfunction in Fabry\u2019s disease. Am Heart J 120:438\u2013440. https:\/\/doi.org\/10.1016\/0002-8703(90)90096-g","journal-title":"Am Heart J"},{"key":"10370_CR36","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1093\/europace\/eul121","volume":"8","author":"M Jastrzebski","year":"2006","unstructured":"Jastrzebski M, Bacior B, Dimitrow PP, Kawecka-Jaszcz K (2006) Electrophysiological study in a patient with Fabry disease and a short PQ interval. Europace 8:1045\u20131047. https:\/\/doi.org\/10.1093\/europace\/eul121","journal-title":"Europace"},{"key":"10370_CR37","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/heartjnl-2019-315933","volume":"106","author":"K Valtola","year":"2020","unstructured":"Valtola K, Nino-Quintero J, Hedman M, Lottonen-Raikaslehto L, Laitinen T, Maria M, Kantola I, Naukkarinen A, Laakso M, Kuusisto J (2020) Cardiomyopathy associated with the Ala143Thr variant of the \u03b1-galactosidase A gene. Heart 106:609\u2013615. https:\/\/doi.org\/10.1136\/heartjnl-2019-315933","journal-title":"Heart"},{"key":"10370_CR38","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/clc.23019","volume":"41","author":"LZ Di","year":"2018","unstructured":"Di LZ, Pichette M, Nadeau R, Bichet DG, Poulin F (2018) Severe bradyarrhythmia linked to left atrial dysfunction in Fabry disease-a cross-sectional study. Clin Cardiol 41:1207\u20131213. https:\/\/doi.org\/10.1002\/clc.23019","journal-title":"Clin Cardiol"},{"key":"10370_CR39","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/jce.15409","volume":"33","author":"L Tassetti","year":"2022","unstructured":"Tassetti L, Fumagalli C, Argir\u00f2 A, Zampieri M, Gori M, Verrillo F, Zocchi C, Cappelli F, Olivotto I (2022) Prevalence and predictors of bradyarrhythmias requiring permanent pacing in patients with Anderson-Fabry disease. J Cardiovasc Electrophysiol 33:1072\u20131078. https:\/\/doi.org\/10.1111\/jce.15409","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10370_CR40","doi-asserted-by":"publisher","first-page":"6235","DOI":"10.1038\/s41598-019-42727-4","volume":"9","author":"D Hern\u00e1ndez-Romero","year":"2019","unstructured":"Hern\u00e1ndez-Romero D, S\u00e1nchez-Qui\u00f1ones J, V\u00edlchez JA, Rivera-Caravaca JM, de la Morena G, Lip GYH, Climent V, Mar\u00edn F (2019) Galectin-3 and \u03b2-trace protein concentrations are higher in clinically unaffected patients with Fabry disease. Sci Rep 9:6235. https:\/\/doi.org\/10.1038\/s41598-019-42727-4","journal-title":"Sci Rep"},{"key":"10370_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-035182","volume":"10","author":"DA Hughes","year":"2020","unstructured":"Hughes DA, Aguiar P, Deegan PB, Ezgu F, Frustaci A, Lidove O, Linhart A, Lubanda JC, Moon JC, Nicholls K, Niu DM, Nowak A, Ramaswami U, Reisin R, Rozenfeld P, Schiffmann R, Svarstad E, Thomas M, Torra R, Vujkovac B, Warnock DG, West ML, Johnson J, Rolfe MJ, Feriozzi S (2020) Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative. BMJ Open 10:e035182. https:\/\/doi.org\/10.1136\/bmjopen-2019-035182","journal-title":"BMJ Open"},{"key":"10370_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2018-000803","volume":"5","author":"D Liu","year":"2018","unstructured":"Liu D, Oder D, Salinger T, Hu K, M\u00fcntze J, Weidemann F, Herrmann S, Ertl G, Wanner C, Frantz S, St\u00f6rk S, Nordbeck P (2018) Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease. Open Heart 5:e000803. https:\/\/doi.org\/10.1136\/openhrt-2018-000803","journal-title":"Open Heart"},{"key":"10370_CR43","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1136\/heartjnl-2020-318271","volume":"108","author":"G Vitale","year":"2022","unstructured":"Vitale G, Ditaranto R, Graziani F, Tanini I, Camporeale A, Lillo R, Rubino M, Panaioli E, Di Nicola F, Ferrara V, Zanoni R, Caponetti AG, Pasquale F, Graziosi M, Berardini A, Ziacchi M, Biffi M, Santostefano M, Liguori R, Taglieri N, Nardi E, Linhart A, Olivotto I, Rapezzi C, Biagini E (2022) Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathy. Heart 108:54\u201360. https:\/\/doi.org\/10.1136\/heartjnl-2020-318271","journal-title":"Heart"},{"key":"10370_CR44","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ijcard.2021.07.022","volume":"339","author":"S Figliozzi","year":"2021","unstructured":"Figliozzi S, Camporeale A, Boveri S, Pieruzzi F, Pieroni M, Lusardi P, Spada M, Mignani R, Burlina A, Graziani F, Pica S, Tondi L, Bernardini A, Chow K, Namdar M, Lombardi M (2021) ECG-based score estimates the probability to detect Fabry disease cardiac involvement. Int J Cardiol 339:110\u2013117. https:\/\/doi.org\/10.1016\/j.ijcard.2021.07.022","journal-title":"Int J Cardiol"},{"key":"10370_CR45","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.acvd.2020.04.008","volume":"113","author":"N Junqua","year":"2020","unstructured":"Junqua N, Legallois D, Segard S, Lairez O, R\u00e9ant P, Goizet C, Maillard H, Charron P, Milliez P, Labombarda F (2020) The value of electrocardiography and echocardiography in distinguishing Fabry disease from sarcomeric hypertrophic cardiomyopathy. Arch Cardiovasc Dis 113:542\u2013550. https:\/\/doi.org\/10.1016\/j.acvd.2020.04.008","journal-title":"Arch Cardiovasc Dis"},{"key":"10370_CR46","doi-asserted-by":"publisher","unstructured":"Lillo R, Pieroni M, Camporeale A, Ciabatti M, Lombardo A, Massetti M, Graziani F (2022) Echocardiography in Anderson-Fabry disease. Rev Cardiovasc Med 3:201. https:\/\/doi.org\/10.31083\/j.rcm2306201","DOI":"10.31083\/j.rcm2306201"},{"key":"10370_CR47","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.119.009013","volume":"12","author":"A Tower-Rader","year":"2019","unstructured":"Tower-Rader A, Jaber WA (2019) Multimodality imaging assessment of Fabry disease. Circ Cardiovasc Imaging 12:e009013. https:\/\/doi.org\/10.1161\/CIRCIMAGING.119.009013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10370_CR48","doi-asserted-by":"publisher","unstructured":"Saccheri MC, Cianciulli TF, Lax JA, Gagliardi JA, C\u00e1ceres GL, Quarin AE, Kisinovsky I, Rozenfeld PA, Reisin RC, AADELFA (2013) Two-dimensional speckle tracking echocardiography for early detection of myocardial damage in young patients with Fabry disease. Echocardiography 30:1069\u20131077. https:\/\/doi.org\/10.1111\/echo.12216","DOI":"10.1111\/echo.12216"},{"key":"10370_CR49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijcard.2021.02.038","volume":"330","author":"R Lillo","year":"2021","unstructured":"Lillo R, Graziani F, Panaioli E, Mencarelli E, Pieroni M, Camporeale A, Manna R, Sicignano LL, Verrecchia E, Lombardo A, Lanza GA, Crea F (2021) Right ventricular strain in Anderson-Fabry disease. Int J Cardiol 330:84\u201390. https:\/\/doi.org\/10.1016\/j.ijcard.2021.02.038","journal-title":"Int J Cardiol"},{"key":"10370_CR50","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.echo.2008.09.002","volume":"21","author":"T Palecek","year":"2008","unstructured":"Palecek T, Dostalova G, Kuchynka P, Karetova D, Bultas J, Elleder M, Linhart A (2008) Right ventricular involvement in Fabry disease. J Am Soc Echocardiogr 21:1265\u20131268. https:\/\/doi.org\/10.1016\/j.echo.2008.09.002","journal-title":"J Am Soc Echocardiogr"},{"key":"10370_CR51","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.echo.2016.11.014","volume":"30","author":"F Graziani","year":"2017","unstructured":"Graziani F, Laurito M, Pieroni M, Pennestr\u00ec F, Lanza GA, Coluccia V, Camporeale A, Pedicino D, Verrecchia E, Manna R, Crea F (2017) Right ventricular hypertrophy, systolic function, and disease severity in Anderson-Fabry disease: an echocardiographic study. J Am Soc Echocardiogr 30:282\u2013291. https:\/\/doi.org\/10.1016\/j.echo.2016.11.014","journal-title":"J Am Soc Echocardiogr"},{"key":"10370_CR52","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1093\/ehjci\/jev057","volume":"16","author":"BN Putko","year":"2015","unstructured":"Putko BN, Yogasundaram H, Chow K, Pagano J, Khan A, Paterson DI, Thompson RB, Oudit GY (2015) Normal left-atrial structure and function despite concentric left-ventricular remodelling in a cohort of patients with Anderson-Fabry disease. Eur Heart J Cardiovasc Imaging 16:1129\u20131136. https:\/\/doi.org\/10.1093\/ehjci\/jev057","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10370_CR53","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.echo.2013.08.024","volume":"26","author":"AC Boyd","year":"2013","unstructured":"Boyd AC, Lo Q, Devine K, Tchan MC, Sillence DO, Sadick N, Richards DA, Thomas L (2013) Left atrial enlargement and reduced atrial compliance occurs early in Fabry cardiomyopathy. J Am Soc Echocardiogr 26:1415\u20131423. https:\/\/doi.org\/10.1016\/j.echo.2013.08.024","journal-title":"J Am Soc Echocardiogr"},{"key":"10370_CR54","doi-asserted-by":"publisher","first-page":"20210020","DOI":"10.1259\/bjr.20210020","volume":"94","author":"G Caredda","year":"2021","unstructured":"Caredda G, Bassareo PP, Cherchi MV, Pontone G, Suri JS, Saba L (2021) Anderson-Fabry disease: role of traditional and new cardiac MRI techniques. Br J Radiol 94:20210020. https:\/\/doi.org\/10.1259\/bjr.20210020","journal-title":"Br J Radiol"},{"key":"10370_CR55","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jacc.2016.07.741","volume":"68","author":"S Nordin","year":"2016","unstructured":"Nordin S, Kozor R, Bulluck H, Castelletti S, Rosmini S, Abdel-Gadir A, Baig S, Mehta A, Hughes D, Moon JC (2016) Cardiac Fabry disease with late gadolinium enhancement is a chronic inflammatory cardiomyopathy. J Am Coll Cardiol 68:1707\u20131708. https:\/\/doi.org\/10.1016\/j.jacc.2016.07.741","journal-title":"J Am Coll Cardiol"},{"key":"10370_CR56","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ehjci\/jeaa101","volume":"22","author":"JB Augusto","year":"2021","unstructured":"Augusto JB, Johner N, Shah D, Nordin S, Knott KD, Rosmini S, Lau C, Alfarih M, Hughes R, Seraphim A, Vijapurapu R, Bhuva A, Lin L, Ojrzy\u0144ska N, Geberhiwot T, Captur G, Ramaswami U, Steeds RP, Kozor R, Hughes D, Moon JC, Namdar M (2021) The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage. Eur Heart J Cardiovasc Imaging 22:790\u2013799. https:\/\/doi.org\/10.1093\/ehjci\/jeaa101","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10370_CR57","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, Germain DP, Hughes DA, Jovanovic A, Kantola I, Linhart A, Mignani R, Monserrat L, Namdar M, Nowak A, Oliveira JP, Ortiz A, Pieroni M, Spada M, Tylki-Szyma\u0144ska A, T\u00f8ndel C, Viana-Baptista M, Weidemann F, Hilz MJ (2018) European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab 124:189\u2013203. https:\/\/doi.org\/10.1016\/j.ymgme.2018.06.004","journal-title":"Mol Genet Metab"},{"key":"10370_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047805","volume":"7","author":"SM Rombach","year":"2012","unstructured":"Rombach SM, Aerts JM, Poorthuis BJ, Groener JE, Donker-Koopman W, Hendriks E, Mirzaian M, Kuiper S, Wijburg FA, Hollak CE, Linthorst GE (2012) Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS ONE 7:e47805. https:\/\/doi.org\/10.1371\/journal.pone.0047805","journal-title":"PLoS ONE"},{"key":"10370_CR59","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1681\/ASN.2018030329","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Brand E (2018) Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry Disease. J Am Soc Nephrol 29:2265\u20132278. https:\/\/doi.org\/10.1681\/ASN.2018030329","journal-title":"J Am Soc Nephrol"},{"key":"10370_CR60","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.2353\/ajpath.2008.070576","volume":"172","author":"C Chimenti","year":"2008","unstructured":"Chimenti C, Hamdani N, Boontje NM, DeCobelli F, Esposito A, Bronzwaer JG, Stienen GJ, Russo MA, Paulus WJ, Frustaci A, van der Velden J (2008) Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease. Am J Pathol 172:1482\u20131490. https:\/\/doi.org\/10.2353\/ajpath.2008.070576","journal-title":"Am J Pathol"},{"key":"10370_CR61","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/eurjhf\/hft104","volume":"15","author":"B Tomberli","year":"2013","unstructured":"Tomberli B, Cecchi F, Sciagr\u00e0 R, Berti V, Lisi F, Torricelli F, Morrone A, Castelli G, Yacoub MH, Olivotto I (2013) Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease. Eur J Heart Fail 15:1363\u20131373. https:\/\/doi.org\/10.1093\/eurjhf\/hft104","journal-title":"Eur J Heart Fail"},{"key":"10370_CR62","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1161\/CIRCEP.114.002569","volume":"8","author":"A Frustaci","year":"2015","unstructured":"Frustaci A, Morgante E, Russo MA, Scopelliti F, Grande C, Verardo R, Franciosa P, Chimenti C (2015) Pathology and function of conduction tissue in Fabry disease cardiomyopathy. Circ Arrhythm Electrophysiol 8:799\u2013805. https:\/\/doi.org\/10.1161\/CIRCEP.114.002569","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10370_CR63","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/hrt.2010.211789","volume":"97","author":"M Namdar","year":"2011","unstructured":"Namdar M, Steffel J, Vidovic M, Brunckhorst CB, Holzmeister J, L\u00fcscher TF, Jenni R, Duru F (2011) Electrocardiographic changes in early recognition of Fabry disease. Heart 97:485\u2013490. https:\/\/doi.org\/10.1136\/hrt.2010.211789","journal-title":"Heart"},{"key":"10370_CR64","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/heartjnl-2018-313699","volume":"105","author":"R Vijapurapu","year":"2019","unstructured":"Vijapurapu R, Nordin S, Baig S, Liu B, Rosmini S, Augusto J, Tchan M, Hughes DA, Geberhiwot T, Moon JC, Steeds RP, Kozor R (2019) Global longitudinal strain, myocardial storage and hypertrophy in Fabry disease. Heart 105:470\u2013476. https:\/\/doi.org\/10.1136\/heartjnl-2018-313699","journal-title":"Heart"},{"key":"10370_CR65","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/ehjci\/jeab214","volume":"23","author":"DY Lu","year":"2022","unstructured":"Lu DY, Huang WM, Wang WT, Hung SC, Sung SH, Chen CH, Yang YJ, Niu DM, Yu WC (2022) Reduced global longitudinal strain as a marker for early detection of Fabry cardiomyopathy. Eur Heart J Cardiovasc Imaging 23:487\u2013495. https:\/\/doi.org\/10.1093\/ehjci\/jeab214","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10370_CR66","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/echo.13496","volume":"34","author":"F Labombarda","year":"2017","unstructured":"Labombarda F, Saloux E, Milesi G, Bienvenu B (2017) Loss of base-to-apex circumferential strain gradient: a specific pattern of Fabry cardiomyopathy? Echocardiography 34:504\u2013510. https:\/\/doi.org\/10.1111\/echo.13496","journal-title":"Echocardiography"},{"key":"10370_CR67","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.echo.2016.10.014","volume":"30","author":"M Pichette","year":"2017","unstructured":"Pichette M, Serri K, Pag\u00e9 M, Di LZ, Bichet DG, Poulin F (2017) Impaired left atrial function in Fabry disease: a longitudinal speckle-tracking echocardiography study. J Am Soc Echocardiogr 30:170-179.e2. https:\/\/doi.org\/10.1016\/j.echo.2016.10.014","journal-title":"J Am Soc Echocardiogr"},{"key":"10370_CR68","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.jcmg.2020.05.011","volume":"13","author":"A Bernardini","year":"2020","unstructured":"Bernardini A, Camporeale A, Pieroni M, Pieruzzi F, Figliozzi S, Lusardi P, Spada M, Mignani R, Burlina A, Carubbi F, Battaglia Y, Graziani F, Pica S, Tondi L, Chow K, Boveri S, Olivotto I, Lombardi M (2020) Atrial dysfunction assessed by cardiac magnetic resonance as an early marker of Fabry cardiomyopathy. JACC Cardiovasc Imaging 13:2262\u20132264. https:\/\/doi.org\/10.1016\/j.jcmg.2020.05.011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10370_CR69","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.118.008424","volume":"12","author":"A Camporeale","year":"2019","unstructured":"Camporeale A, Pieroni M, Pieruzzi F, Lusardi P, Pica S, Spada M, Mignani R, Burlina A, Bandera F, Guazzi M, Graziani F, Crea F, Greiser A, Boveri S, Ambrogi F, Lombardi M (2019) Predictors of clinical evolution in prehypertrophic Fabry disease. Circ Cardiovasc Imaging 12:e008424. https:\/\/doi.org\/10.1161\/CIRCIMAGING.118.008424","journal-title":"Circ Cardiovasc Imaging"},{"key":"10370_CR70","doi-asserted-by":"publisher","unstructured":"Roller FC, Fuest S, Meyer M, Harth S, G\u00fcnd\u00fcz D, Bauer P, Schneider C, Rolfs A, Krombach GA, Tanislav C (2019) Assessment of cardiac involvement in Fabry disease (FD) with native T1 mapping. Rofo 191:932\u2013939. English. https:\/\/doi.org\/10.1055\/a-0836-2723","DOI":"10.1055\/a-0836-2723"},{"key":"10370_CR71","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","volume":"57","author":"MR Patel","year":"2011","unstructured":"Patel MR, Cecchi F, Cizmarik M, Kantola I, Linhart A, Nicholls K, Strotmann J, Tallaj J, Tran TC, West ML, Beitner-Johnson D, Abiose A (2011) Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry. J Am Coll Cardiol 57:1093\u20131099. https:\/\/doi.org\/10.1016\/j.jacc.2010.11.018","journal-title":"J Am Coll Cardiol"},{"key":"10370_CR72","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12968-016-0233-6","volume":"18","author":"DP Deva","year":"2016","unstructured":"Deva DP, Hanneman K, Li Q, Ng MY, Wasim S, Morel C, Iwanochko RM, Thavendiranathan P, Crean AM (2016) Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease. J Cardiovasc Magn Reson 18:14. https:\/\/doi.org\/10.1186\/s12968-016-0233-6","journal-title":"J Cardiovasc Magn Reson"},{"key":"10370_CR73","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ultrasmedbio.2010.10.017","volume":"37","author":"M Niemann","year":"2011","unstructured":"Niemann M, Liu D, Hu K, Herrmann S, Breunig F, Strotmann J, St\u00f6rk S, Voelker W, Ertl G, Wanner C, Weidemann F (2011) Prominent papillary muscles in Fabry disease: a diagnostic marker? Ultrasound Med Biol 37:37\u201343. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2010.10.017","journal-title":"Ultrasound Med Biol"},{"key":"10370_CR74","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1161\/01.CIR.0000061952.27445.A0","volume":"107","author":"M Pieroni","year":"2003","unstructured":"Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A (2003) Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 107:1978\u20131984. https:\/\/doi.org\/10.1161\/01.CIR.0000061952.27445.A0","journal-title":"Circulation"},{"key":"10370_CR75","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.3390\/jcm10091994","volume":"10","author":"R Esposito","year":"2021","unstructured":"Esposito R, Santoro C, Mandoli GE, Cuomo V, Sorrentino R, La Mura L, Pastore MC, Bandera F, D\u2019Ascenzi F, Malagoli A, Benfari G, D\u2019Andrea A, Cameli M (2021) Cardiac imaging in Anderson-Fabry disease: past, present and future. J Clin Med 10:1994. https:\/\/doi.org\/10.3390\/jcm10091994","journal-title":"J Clin Med"},{"key":"10370_CR76","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.119.010171","volume":"13","author":"JB Augusto","year":"2020","unstructured":"Augusto JB, Nordin S, Vijapurapu R, Baig S, Bulluck H, Castelletti S, Alfarih M, Knott K, Captur G, Kotecha T, Ramaswami U, Tchan M, Geberhiwot T, Fontana M, Steeds RP, Hughes D, Kozor R, Moon JC (2020) Myocardial edema, myocyte injury, and disease severity in Fabry disease. Circ Cardiovasc Imaging 13:e010171. https:\/\/doi.org\/10.1161\/CIRCIMAGING.119.010171","journal-title":"Circ Cardiovasc Imaging"},{"key":"10370_CR77","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.119.009430","volume":"12","author":"S Nordin","year":"2019","unstructured":"Nordin S, Kozor R, Vijapurapu R, Augusto JB, Knott KD, Captur G, Treibel TA, Ramaswami U, Tchan M, Geberhiwot T, Steeds RP, Hughes DA, Moon JC (2019) Myocardial storage, inflammation, and cardiac phenotype in Fabry disease after one year of enzyme replacement therapy. Circ Cardiovasc Imaging 12:e009430. https:\/\/doi.org\/10.1161\/CIRCIMAGING.119.009430","journal-title":"Circ Cardiovasc Imaging"},{"key":"10370_CR78","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/01.CIR.0000139847.74101.03","volume":"110","author":"C Chimenti","year":"2004","unstructured":"Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, Maseri A, Frustaci A (2004) Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 110:1047\u20131053. https:\/\/doi.org\/10.1161\/01.CIR.0000139847.74101.03","journal-title":"Circulation"},{"key":"10370_CR79","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.clinthera.2009.09.008","volume":"31","author":"C Kampmann","year":"2009","unstructured":"Kampmann C, Linhart A, Devereux RB, Schiffmann R (2009) Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis. Clin Ther 31:1966\u20131976. https:\/\/doi.org\/10.1016\/j.clinthera.2009.09.008","journal-title":"Clin Ther"},{"key":"10370_CR80","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","volume":"8","author":"M Lenders","year":"2022","unstructured":"Lenders M, Nordbeck P, Kurschat C, Eveslage M, Karabul N, Kaufeld J, Hennermann JB, Patten M, Cybulla M, M\u00fcntze J, \u00dc\u00e7eyler N, Liu D, Das AM, Sommer C, Pogoda C, Reiermann S, Duning T, Gaedeke J, von Cossel K, Blaschke D, Brand SM, Mann WA, Kampmann C, Muschol N, Canaan-K\u00fchl S, Brand E (2022) Treatment of Fabry disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS). Eur Heart J Cardiovasc Pharmacother 8:272\u2013281. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10370_CR81","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/hrt.2006.104026","volume":"94","author":"DA Hughes","year":"2008","unstructured":"Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94:153\u2013158. https:\/\/doi.org\/10.1136\/hrt.2006.104026","journal-title":"Heart"},{"key":"10370_CR82","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.acvd.2019.01.002","volume":"112","author":"A Hag\u00e8ge","year":"2019","unstructured":"Hag\u00e8ge A, R\u00e9ant P, Habib G, Damy T, Barone-Rochette G, Soulat G, Donal E, Germain DP (2019) Fabry disease in cardiology practice: literature review and expert point of view. Arch Cardiovasc Dis 112:278\u2013287. https:\/\/doi.org\/10.1016\/j.acvd.2019.01.002","journal-title":"Arch Cardiovasc Dis"},{"key":"10370_CR83","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccep.2015.03.014","volume":"7","author":"D Acharya","year":"2015","unstructured":"Acharya D, Doppalapudi H, Tallaj JA (2015) Arrhythmias in Fabry cardiomyopathy. Card Electrophysiol Clin 7:283\u2013291. https:\/\/doi.org\/10.1016\/j.ccep.2015.03.014","journal-title":"Card Electrophysiol Clin"},{"key":"10370_CR84","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/ejhf.1960","volume":"22","author":"A Linhart","year":"2020","unstructured":"Linhart A, Germain DP, Olivotto I, Akhtar MM, Anastasakis A, Hughes D, Namdar M, Pieroni M, Hag\u00e8ge A, Cecchi F, Gimeno JR, Limongelli G, Elliott P (2020) An expert consensus document on the management of cardiovascular manifestations of Fabry disease. Eur J Heart Fail 22:1076\u20131096. https:\/\/doi.org\/10.1002\/ejhf.1960","journal-title":"Eur J Heart Fail"},{"key":"10370_CR85","doi-asserted-by":"publisher","unstructured":"Authors TF, members; Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733\u20132779. https:\/\/doi.org\/10.1093\/eurheartj\/ehu284","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"10370_CR86","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1540-8175.2005.03191.x","volume":"22","author":"S Magage","year":"2005","unstructured":"Magage S, Linhart A, Bultas J, Vojacek J, Mates M, Palecek T, Popelova J, Tintera J, Aschermann M, Goldman ME, Desnick RJ (2005) Fabry disease: percutaneous transluminal septal myocardial ablation markedly improved symptomatic left ventricular hypertrophy and outflow tract obstruction in a classically affected male. Echocardiography 22:333\u2013339. https:\/\/doi.org\/10.1111\/j.1540-8175.2005.03191.x","journal-title":"Echocardiography"},{"key":"10370_CR87","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.athoracsur.2012.05.087","volume":"95","author":"MR Kunkala","year":"2013","unstructured":"Kunkala MR, Aubry MC, Ommen SR, Gersh BJ, Schaff HV (2013) Outcome of septal myectomy in patients with Fabry\u2019s disease. Ann Thorac Surg 95:335\u2013337. https:\/\/doi.org\/10.1016\/j.athoracsur.2012.05.087","journal-title":"Ann Thorac Surg"},{"key":"10370_CR88","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","volume":"4","author":"M Niemann","year":"2011","unstructured":"Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, Machann W, Voelker W, Ertl G, Wanner C, Weidemann F (2011) Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging 4:592\u2013601. https:\/\/doi.org\/10.1016\/j.jcmg.2011.01.020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10370_CR89","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/diseases4040031","volume":"4","author":"M De La Mata","year":"2016","unstructured":"De La Mata M, Cot\u00e1n D, Villanueva-Paz M, De Lavera I, \u00c1lvarez-C\u00f3rdoba M, Luz\u00f3n-Hidalgo R, Su\u00e1rez-Rivero JM, Tiscornia G, Oropesa-\u00c1vila M (2016) Mitochondrial dysfunction in lysosomal storage disorders. Diseases 4:31. https:\/\/doi.org\/10.3390\/diseases4040031","journal-title":"Diseases"},{"key":"10370_CR90","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3390\/ijms22031331","volume":"22","author":"D Sorriento","year":"2021","unstructured":"Sorriento D, Iaccarino G (2021) The cardiovascular phenotype in Fabry disease: new findings in the research field. Int J Mol Sci 22:1331. https:\/\/doi.org\/10.3390\/ijms22031331","journal-title":"Int J Mol Sci"},{"key":"10370_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131357","volume":"393","author":"A Moroni","year":"2023","unstructured":"Moroni A, Tondi L, Milani V, Pieroni M, Pieruzzi F, Bevilacqua F, Pasqualin G, Chow K, Pica S, Lombardi M, Camporeale A (2023) Left atrial remodeling in hypertrophic cardiomyopathy and Fabry disease: a CMR-based head-to-head comparison and outcome analysis. Int J Cardiol 393:131357. https:\/\/doi.org\/10.1016\/j.ijcard.2023.131357","journal-title":"Int J Cardiol"},{"key":"10370_CR92","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/ehf2.12712","volume":"7","author":"F Graziani","year":"2020","unstructured":"Graziani F, Lillo R, Panaioli E, Pieroni M, Camporeale A, Verrecchia E, Sicignano LL, Manna R, Lombardo A, Lanza GA, Crea F (2020) Prognostic significance of right ventricular hypertrophy and systolic function in Anderson-Fabry disease. ESC Heart Fail 7:1605\u20131614. https:\/\/doi.org\/10.1002\/ehf2.12712","journal-title":"ESC Heart Fail"},{"key":"10370_CR93","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/ajmg.a.40369","volume":"176","author":"AW Powell","year":"2018","unstructured":"Powell AW, Jefferies JL, Hopkin RJ, Mays WA, Goa Z, Chin C (2018) Cardiopulmonary fitness assessment on maximal and submaximal exercise testing in patients with Fabry disease. Am J Med Genet A 176:1852\u20131857. https:\/\/doi.org\/10.1002\/ajmg.a.40369","journal-title":"Am J Med Genet A"},{"key":"10370_CR94","doi-asserted-by":"publisher","unstructured":"Meucci MC, Lillo R, Lombardo A, Lanza GA, Bootsma M, Butcher SC, Massetti M, Manna R, Bax JJ, Crea F, Ajmone Marsan N, Graziani F (2023) Comparative analysis of right ventricular strain in Fabry cardiomyopathy and sarcomeric hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging 24:542\u2013551. https:\/\/doi.org\/10.1093\/ehjci\/jeac151","DOI":"10.1093\/ehjci\/jeac151"},{"key":"10370_CR95","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ijcard.2022.12.047","volume":"374","author":"MC Meucci","year":"2023","unstructured":"Meucci MC, Lillo R, Mango F, Lombardo A, Lanza GA, Parisi V, Grandinetti M, Massetti M, Ajmone Marsan N, Crea F, Graziani F (2023) Right ventricular strain in Fabry disease: Prognostic implications. Int J Cardiol 374:79\u201382. https:\/\/doi.org\/10.1016\/j.ijcard.2022.12.047","journal-title":"Int J Cardiol"},{"key":"10370_CR96","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/joim.12077","volume":"274","author":"F Weidemann","year":"2013","unstructured":"Weidemann F, Niemann M, St\u00f6rk S, Breunig F, Beer M, Sommer C, Herrmann S, Ertl G, Wanner C (2013) Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 274:331\u2013341. https:\/\/doi.org\/10.1111\/joim.12077","journal-title":"J Intern Med"},{"key":"10370_CR97","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","volume":"53","author":"A Ortiz","year":"2016","unstructured":"Ortiz A, Abiose A, Bichet DG, Cabrera G, Charrow J, Germain DP, Hopkin RJ, Jovanovic A, Linhart A, Maruti SS, Mauer M, Oliveira JP, Patel MR, Politei J, Waldek S, Wanner C, Yoo HW, Warnock DG (2016) Time to treatment benefit for adult patients with Fabry disease receiving agalsidase \u03b2: data from the Fabry Registry. J Med Genet 53:495\u2013502. https:\/\/doi.org\/10.1136\/jmedgenet-2015-103486","journal-title":"J Med Genet"},{"key":"10370_CR98","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jjcc.2007.12.001","volume":"51","author":"T Takenaka","year":"2008","unstructured":"Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Ninomiya K, Umekita Y, Yoshida H, Horinouchi M, Tabata K, Yonezawa S, Yoshimitsu M, Higuchi K, Nakao S, Anan R, Minagoe S, Tei C (2008) Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol 51:50\u201359. https:\/\/doi.org\/10.1016\/j.jjcc.2007.12.001","journal-title":"J Cardiol"},{"key":"10370_CR99","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.jcmg.2022.03.004","volume":"15","author":"F Graziani","year":"2022","unstructured":"Graziani F, Leccisotti L, Lillo R, Bruno I, Ingrasciotta G, Leone AM, Montone RA, Marano R, Rovere G, Indovina L, Camporeale A, Pieroni M, Giordano A, Manna R, Lombardo A, Massetti M, Lanza GA, Crea F (2022) Coronary microvascular dysfunction is associated with a worse cardiac phenotype in patients with Fabry disease. JACC Cardiovasc Imaging 15:1518\u20131520. https:\/\/doi.org\/10.1016\/j.jcmg.2022.03.004","journal-title":"JACC Cardiovasc Imaging"},{"key":"10370_CR100","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ijcard.2022.07.046","volume":"369","author":"F Graziani","year":"2022","unstructured":"Graziani F, Lillo R, Biagini E, Limongelli G, Autore C, Pieroni M, Lanzillo C, Cal\u00f2 L, Musumeci MB, Ingrasciotta G, Minnucci M, Ditaranto R, Milazzo A, Zocchi C, Rubino M, Lanza GA, Olivotto I, Crea F (2022) Myocardial infarction with non-obstructive coronary arteries in hypertrophic cardiomyopathy vs Fabry disease. Int J Cardiol 369:29\u201332. https:\/\/doi.org\/10.1016\/j.ijcard.2022.07.046","journal-title":"Int J Cardiol"},{"key":"10370_CR101","doi-asserted-by":"publisher","unstructured":"Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34:236\u2013242. https:\/\/doi.org\/10.1111\/j.1365-2362.2004.01309.x. PMID: 15025684","DOI":"10.1111\/j.1365-2362.2004.01309.x"},{"key":"10370_CR102","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/01.SMJ.0000052065.86839.9A","volume":"96","author":"A Blum","year":"2003","unstructured":"Blum A, Ashkenazi H, Haromankov I, Khazim K, Sheiman J (2003) First-degree atrioventricular block and restrictive physiology as cardiac manifestations of Fabry\u2019s disease. South Med J 96:212\u2013213. https:\/\/doi.org\/10.1097\/01.SMJ.0000052065.86839.9A","journal-title":"South Med J"},{"key":"10370_CR103","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","volume":"10","author":"M Biegstraaten","year":"2015","unstructured":"Biegstraaten M, Arngr\u00edmsson R, Barbey F, Boks L, Cecchi F, Deegan PB, Feldt-Rasmussen U, Geberhiwot T, Germain DP, Hendriksz C, Hughes DA, Kantola I, Karabul N, Lavery C, Linthorst GE, Mehta A, van de Mheen E, Oliveira JP, Parini R, Ramaswami U, Rudnicki M, Serra A, Sommer C, Sunder-Plassmann G, Svarstad E, Sweeb A, Terryn W, Tylki-Szymanska A, T\u00f8ndel C, Vujkovac B, Weidemann F, Wijburg FA, Woolfson P, Hollak CE (2015) Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis 10:36. https:\/\/doi.org\/10.1186\/s13023-015-0253-6","journal-title":"Orphanet J Rare Dis"},{"key":"10370_CR104","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","volume":"119","author":"F Weidemann","year":"2009","unstructured":"Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, St\u00f6rk S, Voelker W, Ertl G, Wanner C, Strotmann J (2009) Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119:524\u2013529. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.794529","journal-title":"Circulation"}],"updated-by":[{"DOI":"10.1007\/s10741-023-10379-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000}}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10370-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-023-10370-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10370-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T08:18:29Z","timestamp":1710749909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-023-10370-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,25]]},"references-count":104,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["10370"],"URL":"https:\/\/doi.org\/10.1007\/s10741-023-10370-x","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,25]]},"assertion":[{"value":"6 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10741-023-10379-2","URL":"https:\/\/doi.org\/10.1007\/s10741-023-10379-2","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}